Propanc Biopharma, Inc.

Over the past 90 days, Propanc Biopharma (PPCB) has reported zero cyber incidents and zero red-flag 8-K filings, suggesting operational stability in our near-term monitoring window. However, a quiet recent period does not eliminate fundamental risks; biotech companies face persistent dilution pressure, financing dependency, and sector-specific volatility that require deeper historical context. The full $49 Report extends analysis across 12 months of SEC filings, applies our dilution risk scoring model, maps financing history and runway, and flags emerging AI-detected signals that shorter windows miss. The full $49 Report adds quantified dilution trajectory, officer and insider transaction patterns, and forward-looking capital structure stress scenarios.